MindMed Reports Q2 2025 Financial Results and Business Updates
Mind Medicine (MindMed) Inc. - Common Shares (MNMD)
Company Research
Source: Business Wire
--Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)----Data from the Phase 3 Voyage trial in GAD anticipated in 1H 2026 and data from the Phase 3 Panorama trial in GAD and Phase 3 Emerge trial in MDD anticipated in 2H 2026----Strengthened leadership team with appointment of Brandi L. Roberts as Chief Financial Officer----Conference call scheduled today at 4:30 p.m. EDT-- NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its second quarter 2025 financial results and provided an update on business highlights.“We continue making significant progress across all three of our pivotal Phase 3 trials evaluating MM120 ODT in GAD and MDD, with ongoing enthusiasm from both trial sites and
Show less
Read more
Impact Snapshot
Event Time:
MNMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNMD alerts
High impacting Mind Medicine (MindMed) Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MNMD
News
- Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026 [Yahoo! Finance]Yahoo! Finance
- Mind Medicine (MindMed) (NASDAQ:MNMD) is now covered by analysts at Jones Trading. They set a "buy" rating and a $61.00 price target on the stock.MarketBeat
- Psychedelics stocks could benefit from marijuana rescheduling: Jefferies [Seeking Alpha]Seeking Alpha
- Assessing Mind Medicine (MNMD)'s Valuation After Strong Multi-Year Share Price Gains [Yahoo! Finance]Yahoo! Finance
- MindMed to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
MNMD
Earnings
- 11/6/25 - Miss
MNMD
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- MNMD's page on the SEC website